A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.

A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer. 2016 Feb; 14(1):22-7.

View in: PubMed

subject areas

Adenocarcinoma
Aged
Aged, 80 and over
Androgen Antagonists
Antineoplastic Combined Chemotherapy Protocols
Bone Neoplasms
Gossypol
Humans
Lymphatic Metastasis
Male
Middle Aged
Prostatic Neoplasms
Treatment Outcome

authors with profiles

Walter M. Stadler